The ESMO clinical practice guidelines for cancer prevention and screening in BRCA mutation carriers report that the association between BRCA1/BRCA2 mutations and an elevated risk of endometrial cancer remains weak [36]. This evidence concerns the gene BRCA2 and endometrial cancer.